Angelini Ventures sells Noctrix Health to ResMed
The deal brings Nidra, an FDA-authorized non-invasive therapy for moderate-to-severe restless legs syndrome, into a broader sleep health and respiratory care business.
Takeaways
- Noctrix Health is a developer of non-invasive neuromodulation therapy for restless legs syndrome.
- Angelini Ventures is exiting Noctrix Health through a sale to ResMed.
- The business serves patients with restless legs syndrome.
Noctrix Health, developer of wearable non-invasive neuromodulation therapy for restless legs syndrome, moved to ResMed in a transaction valued at $340 million.
Founded in 2016, the medical technology company develops clinically validated therapies for chronic neurological and sleep-related conditions.
Its lead product, Nidra, is FDA-authorized for moderate-to-severe restless legs syndrome.
Angelini Ventures invested in Noctrix Health in 2024 as part of the company’s $40 million Series C financing round, supporting clinical and commercial development.
ResMed plans to integrate Nidra into its sleep health ecosystem to reach more patients with RLS.
“It has been a privilege to partner with the Noctrix team during such a pivotal phase of the company’s growth,” added Tanja Dowe, Managing Director at Angelini Ventures and Board Observer at Noctrix Health prior to the acquisition.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.